Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen to Go Commercial With Macdonald

Premium

David Macdonald’s come a long way from building weapons systems. After his start at Raytheon in his native Boston, he ventured into science and hasn’t left since. Now senior vice president of operations at Nanogen, Macdonald says his job will be “taking the technologies that have been developed here over the past eight years and turning them into products that we can commercialize.” Nanogen will be a leader in making routine clinical molecular diagnostics, he believes; it’s just a matter of selling.

Formerly president of two linked San Diego startups — one in animal fertility, one in human — Macdonald decided not to relocate when the firms moved to Israel. For about eight years before that, he headed up the Nichols Institute diagnostics division, which Corning bought and spun out as Quest Diagnostics.

Eager to stay in the San Diego area, “I sent a letter to Nanogen and they were intrigued by my background,” says Macdonald, who will focus on getting market share away from homebrew tests to carve out a niche for his company’s products.

— Meredith Salisbury

 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more